Why the study?
The efficacy and safety of intrapericardial treatment with the crystalloid corticosteroid triamcinolone in autoreactive pericardial effusion to avoid the side effects of systemic corticosteroid therapy required evaluation.
Does intrapericardial triamcinolone 300 mg/m2/24h compared to 600 mg/m2/24h reduce side effects while maintaining efficacy in preventing effusion recurrence in patients with autoreactive pericarditis?
Does intrapericardial triamcinolone 300 mg/m2/24h compared to 600 mg/m2/24h reduce side effects while maintaining efficacy in preventing effusion recurrence in patients with autoreactive pericarditis?
Intrapericardial triamcinolone at 300 mg/m2/24h is as effective as 600 mg/m2/24h for preventing recurrence of autoreactive pericarditis but with significantly fewer side effects like iatrogenic Cushing syndrome.
Answers are grounded in this paper and cite their sources.
May favor 300 mg/m2/24h intrapericardial triamcinolone to limit Cushing syndrome; leaves open randomized confirmation of equivalent efficacy.
AIMS: To evaluate efficacy and safety of intrapericardial treatment with the crystalloid corticosteroid triamcinolone in autoreactive pericardial effusion. METHODS AND RESULTS: Two hundred and sixty consecutive patients with pericarditis/myopericarditis underwent pericardiocentesis, pericardioscopy (Storz-AF1101B1), and epicardial biopsy with pericardial fluid and tissue analyses. By polymerase chain reaction for cardiotropic viruses/bacteria in pericardial effusion and epicardial biopsies as well as by immunohistochemistry and immunocytochemistry of epicardial and endomyocardial biopsies, 84/260 patients were classified as autoreactive pericarditis and underwent intrapericardial instillation of triamcinolone (group 1: 54 patients, 50% males, mean age 48.9 +/- 14.3 years, triamcinolone 600 mg x m(-2) x 24 h(-1); group 2: 30 patients, 46.7% males, mean age 52.5 +/- 12.7 years, triamcinolone 300 mg x m(-2) x 24 h(-1)). Intrapericardial administration of triamcinolone resulted in symptomatic improvement and prevented effusion recurrence in 92.6% vs 86.7% of the patients after 3 months and in 86.0% vs 82.1% after 1 year in groups 1 and 2, respectively (P>0.05). There were no treatment-related acute complications. During the follow-up, 29.6% of the patients developed transitory iatrogenic Cushing syndrome in group 1 in contrast to 13.3% in group 2 (P<0.05). Conclusion Intrapericardial treatment of autoreactive pericarditis with 300 mg x m(-2) x 24 h(-1) of triamcinolone prevented recurrence of symptoms and relapse of effusion as effectively as the 600 mg x m(-2) x 24 h(-1) regimen, but with significantly fewer side effects.
No takes yet. Share an insight, caveat, or question.
Bernhard Maisch (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: